Compare Grab Holdings Ltd. (GRAB) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Mesoblast Limited — how do they compare? Grab Holdings Ltd. trades at $3.13 (market cap $12.60B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Grab Holdings Ltd. is far larger — about 7× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (240,620 versus 87,608,440). Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and Mesoblast Limited for 14 Days on average.
| GRAB | MESO | |
|---|---|---|
Market Cap | $12.60B | $1.81B |
Volume | 87,608,440 | 240,620 |
Sector | Technology | Health |
52-Week High | $6.17 | $20.96 |
52-Week Low | $2.80 | $13.19 |
Typical Hold Time | 94 Days | 14 Days |
Enterprise Value | $8.33B | $1.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.11, up 1.3% today, with a bearish technical signal but strong fundamentals including a 22% YoY revenue growth in Q2 2026 and a net income margin of 16.03%. Recent news highlights a $30 million CEO share purchase and the acquisition of a 60% stake in Atome Financial for $1.49 billion, signaling confidence and expansion in financial services.
The outlook is positive with robust earnings beats and a 91.67% analyst buy rating, though risks include high capital expenditure, regional regulatory challenges, and volatile cash flows. The stock's current valuation at a P/E of 28 reflects growth expectations amid competitive pressures.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
